22-Jul-2026
Best ETFs to Invest In, According to AI Analyst, 7/22/2026
TipRanks (Wed, 22-Jul 2:04 PM ET)
TipRanks (Wed, 22-Jul 7:15 AM ET)
Business Wire (Tue, 21-Jul 10:00 AM ET)
Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure
Business Wire (Tue, 21-Jul 10:00 AM ET)
Alpha Tau rises on Alpha DaRT head and neck cancer data
Seeking Alpha News (Tue, 21-Jul 9:21 AM ET)
Dow leadership shifts to value sectors amid broad market rotation
Seeking Alpha News (Mon, 20-Jul 12:08 PM ET)
Business Wire (Thu, 16-Jul 6:45 AM ET)
Merck Unveils Promising Once-Weekly and Monthly HIV Treatments—Key Data to Be Presented at AIDS 2026
Market Chameleon (Wed, 15-Jul 3:29 AM ET)
Business Wire (Wed, 15-Jul 7:00 AM ET)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
Merck Common (New) trades on the NYSE stock market under the symbol MRK.
As of July 22, 2026, MRK stock price climbed to $127.47 with 6,340,304 million shares trading.
MRK has a beta of 0.12, meaning it tends to be less sensitive to market movements. MRK has a correlation of 0.00 to the broad based SPY ETF.
MRK has a market cap of $314.83 billion. This is considered a Mega Cap stock.
Last quarter Merck Common (New) reported $16 billion in Revenue and -$1.28 earnings per share. This beat revenue expectation by $429 million and exceeded earnings estimates by $.20.
In the last 3 years, MRK traded as high as $134.63 and as low as $73.31.
The top ETF exchange traded funds that MRK belongs to (by Net Assets): VTI, VOO, SCHD, IVV, SPY.
MRK has outperformed the market in the last year with a return of +65.0%, while the SPY ETF gained +20.1%. In the last 3 month period, MRK beat the market returning +14.0%, while SPY returned +6.4%. However, in the most recent 2 weeks MRK has underperformed the stock market by returning -1.1%, while SPY returned 0.0%.
MRK support price is $123.69 and resistance is $128.83 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MRK shares will trade within this expected range on the day.